31 July 2025 Xtep announced its 2Q25 operational results, with retail sales for its Xtep Core Brand recorded a LSD growth YoY, slowing down from MSD/+10% growth in 1Q25/2Q24. Breaking down by month, sales in April/May were better than June,
24 July 2025 In July, Minth announced that it has entered into the Development Commission Service Agreement and Strategic Cooperation with EHang (EH US, NR) to which the parties agreed to the framework of cooperation to jointly develop and operate
18 Jul 2025 Anta announced its 2Q25 operational results, with retail sales for its Anta Core Brand recorded a LSD growth YoY (1Q25: +HSD, 4Q24: +HSD), with 1H25 up by MSD YoY. Both adults and kids sales grew by LSD
15 Jul 2025 361 Degrees announced its 2Q25 operational results, with offline retail sales for its 361° Core Brand recorded a ~10% growth YoY (1Q25: +10%-15%, 2Q24: +10%), while 361° Kids was up by ~10% growth YoY (1Q25: +10%-15%, 2Q24:
17 July 2025 Johnson Electric (JE) announced that it has entered into two JV agreements with Shanghai Mechanical & Electrical Industry. JE’s total investment in these two JVs amounted to Rmb75m.
15 July 2025 Wasion announced that it has been awarded a smart meter tender contract by Mexico’s Federal Electricity Commission (CFE) last month, valued at over MXN627.4m. This was followed by a previous supply agreement signed with CFE in March
15 Jul 2025 Handset Lens Sets (HLS) shipment in Jun was down by 3.1% MoM and 12.7% YoY to 95.1m units. This decline was primarily due to a strategic focus on mid-to-high end projects. With the accelerated application of higher
05 June 2025 According to data released by the Hong Kong Census and Statistics Department, retail sales in April 2025 declined for the 14th consecutive month, dropping by 2.3% YoY to an estimated HK$28.9bn, falling short of market expectations, which
2 Jun 2025
2 Jun 2025 Based in Hong Kong, SinoMab is a pioneering biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of therapeutics for immunological diseases, with a primary focus on monoclonal antibody (mAb)-based biologics. Since its inception, SinoMab has
